At 10:25 IST, the barometer index, the S&P BSE Sensex, was up 834 points or 1.7% at 49,934.67. The Nifty 50 index was up 244.55 points or 1.68% at 14,773.30.
In broader market, the S&P BSE Mid-Cap index was up 1.15% while the S&P BSE Small-Cap index was up 1.43%.
The market breadth, indicating the overall health of the market, was strong. On the BSE, 1889 shares rose and 687 shares fell. A total of 159 shares were unchanged.
Economy:
The seasonally adjusted IHS Markit India Manufacturing Purchasing Managers' Index (PMI) stood at 57.5 in February 2021, highlighting a strong improvement in operating conditions that was broadly similar to that recorded in January (57.7). The headline figure remained above its long-run average of 53.6.
India's economy returned to growth in its fiscal third quarter after a recession earlier in 2020. Gross domestic product grew 0.4% in October-December compared with the same period a year earlier, data released by the National Statistics Office on Friday showed. That compared with revised contractions of 7.3% in July-September and 24.4% in April-June.
The output of eight core infrastructure sectors grew marginally by 0.1% in January, mainly due to growth in the production of fertiliser, steel and electricity. The core sectors had expanded by 2.2% in January 2020, according to the provisional data released by the Commerce and Industry Ministry on Friday.
COVID-19 Update:
Total COVID-19 confirmed cases worldwide stood at 114,051,765 with 25,30,563 deaths. India reported 168,627 active cases of COVID-19 infection and 157,157 deaths while 107,86,457 patients have been discharged, according to the data from the Ministry of Health and Family Welfare, Government of India.
Buzzing Index:
The Nifty IT index surged 1.66% to 24,704.30 on bargain hunting after tumbling 2.3% in previous trading session.
Tech Mahindra (up 3.2%), HCL Tech (up 2.19%), TCS (up 2.06%), Infosys (up 1.65%), Wipro (up 1.27%), Info Edge (up 0.95%) and Coforge (up 0.43%) were top gainers in IT segment.
Stocks in Spotlight:
KEC International advanced 2.92% after the EPC company bagged new orders of Rs 1,140 crore across its various businesses.
Biocon gained 0.63%. Biocon Biologics, a subsidiary of Biocon, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of their biosimilar Bevacizumab, co-developed with Viatris, to be marketed as Abevmy (injection bevacizumab 100 mg and 400 mg).
Abevmy is a biosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
